# Research timeline and gaps: Microplastics and Cardiovascular Disease

Selected publication milestones, not an exhaustive history or discovery priority claim.

**2016 — Repeated PIVUS sampling maps compound-specific serum trends; kinetics is distinct from clinical risk.** [Original PMID27542758](https://pubmed.ncbi.nlm.nih.gov/27542758/).

**2017 — Contaminated-water distribution predicts PFHxS trends within the shared PIVUS cohort.** [Original PMID28780137](https://pubmed.ncbi.nlm.nih.gov/28780137/).

**2019 — Prospective PFAS-diabetes results include mostly nonsignificant inverse associations, a boundary against uniform metabolic-harm inference.** [Original PMID30622063](https://pubmed.ncbi.nlm.nih.gov/30622063/).

**2021 — Particle-exposed endothelial/immune models demonstrate activation while leaving human clinical dependency unresolved.** [Original PMID34788346](https://pubmed.ncbi.nlm.nih.gov/34788346/).

**2022 — A contamination-aware pyrolysis workflow detects polymer mass in human blood.** [Original PMID35367073](https://pubmed.ncbi.nlm.nih.gov/35367073/).

**2022 — Randomized donation lowers selected serum PFAS without established clinical health improvement.** [Original PMID35394514](https://pubmed.ncbi.nlm.nih.gov/35394514/).

**2022 — Anionic particles produce biophysical endothelial leakiness, broadening mechanisms beyond inflammatory markers.** [Original PMID35963861](https://pubmed.ncbi.nlm.nih.gov/35963861/).

**2023 — A sensitized high-fat ApoE mouse platform shows administered particle-associated atherosclerosis; dose translation remains open.** [Original PMID37144527](https://pubmed.ncbi.nlm.nih.gov/37144527/).

**2023 — Cardiac-surgery tissue and paired blood analyses highlight clinical procedural sources and diseased-tissue selection.** [Original PMID37440474](https://pubmed.ncbi.nlm.nih.gov/37440474/).

**2024 — A prospective carotid-surgery cohort links plaque polymers to later infarction, stroke or all-cause death, without proving causality.** [Original PMID38446676](https://pubmed.ncbi.nlm.nih.gov/38446676/).

**2024 — Randomized-sequence resin treatment lowers serum PFAS; concentration is its primary outcome.** [Original PMID38367552](https://pubmed.ncbi.nlm.nih.gov/38367552/).

**2024 — Barrier impairment associates with CNS particle burden without a particle-cytokine association.** [Original PMID39366047](https://pubmed.ncbi.nlm.nih.gov/39366047/).

**2025 — A post-MI clinical cohort adds coronary PVC/event association, with ambiguous indexed numerical wording retained as a limitation.** [Original PMID40007360](https://pubmed.ncbi.nlm.nih.gov/40007360/).

**2025 — Mouse imaging demonstrates particle-phagocyte obstruction and reduced microvascular flow under administered exposure.** [Original PMID39841831](https://pubmed.ncbi.nlm.nih.gov/39841831/).

**2025 — Prospective PFAS/lipidomics case-control work links chemicals with post-PCI events, while causal mediation remains unisolated.** [Original PMID40571603](https://pubmed.ncbi.nlm.nih.gov/40571603/).

**2025 — Lean LDLR-deficient mice show a male-versus-female atherosclerosis boundary under daily gavage.** [Original PMID41275764](https://pubmed.ncbi.nlm.nih.gov/41275764/).

**2025 — Small crossover interventions distinguish enhanced chemical excretion from serum concentration and clinical benefit.** [Original PMID40974835](https://pubmed.ncbi.nlm.nih.gov/40974835/).

## Research gaps

Standardized particle-resolved internal dosimetry and procedural contamination controls across human cohorts.

Independent prospective clinical-event cohorts outside pre-existing disease/surgical selection, with cardiovascular death separated from all-cause death.

Validated natural exposure-mitigation contrasts and causal instruments; no unethical deliberate human exposure trial is required.

Realistic dose, polymer/size/surface, sex/genotype and additive controls for mediator-specific vascular experiments.

Controlled human plastic-particle burden removal with clinical benefit-harm endpoints, distinct from chemical serum kinetics.

Compound-specific PFAS clinical-event attribution and controlled removal-health outcomes, rather than extrapolation from lipids or blood concentration.

## Boundary experiment

A prospective natural exposure-mitigation study compares baseline-defined communities affected by a specific verified source with matched independent control communities. Register polymer/particle sizes, chemical coexposures, repeated internal-dose assays, clean procedural blanks, baseline vascular risk and adjudicated myocardial infarction/stroke/cardiovascular-death endpoints. Separately randomize a lawful safe chemical-burden-lowering strategy in appropriately eligible PFAS-exposed adults to prespecified clinical function/health and harm outcomes; do not equate serum decline with success.